Loading stock data…
Myriad Genetics, Inc. (MYGN)
$5.85-0.03 (-0.51%)
After Hours$5.85+0.00 (+0.00%)· Last close Jun 29
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Myriad Genetics, Inc. in the Healthcare sector is trading at $5.85 with a market capitalization of $416M. Wall Street consensus targets $6.25 (8 analysts), implying a +6.8% move over the next 12 months. The stock is currently 32% below its 52-week high of $8.59, remaining 0.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +6.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $200.40M↓ | $209.80M↑ | $205.70M↓ | $213.10M↑ | $195.90M |
| Gross Profit | $137.60M↓ | $146.80M↑ | $143.80M↓ | $151.80M↑ | $134.20M |
| Operating Income | -$25.30M↓ | -$3.00M↑ | -$23.30M↓ | -$12.50M↑ | -$29.00M |
| Net Income | -$34.10M↓ | -$7.90M↑ | -$27.40M↑ | -$330.50M↓ | -$100,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$415.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.64
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-118.52%
Volume
Today's trading volume
1.93M
Recent News
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 9.2% in the morning session after the company expanded the availability of its Precise MRD test for breast, colorectal, and renal cancers and announced positive results from a clinical study.
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
3 High-Flying Stocks We’re Skeptical Of
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.